Introduction {#Sec1}
============

Atypical subtrochanteric or femoral shaft fractures occasionally show delayed union, especially in osteoporosis patients undergoing long-term treatment with bisphosphonates. However, there have been few published studies on the effects of pharmacotherapy on these fractures. Previous studies have suggested that teriparatide (TPTD) therapy can be effective to promote healing of fractures with delayed unions \[[@CR1]--[@CR6]\]. However, it is still unknown whether a once-weekly administration of TPTD could offer an effective alternative to the daily TPTD. Herein, the authors report a patient with delayed union after surgery for an atypical femoral fracture (AFF) who was effectively treated with once-weekly administration of 56.5 μg of TPTD.

Case report {#Sec2}
===========

A 74-year-old female patient with osteoporosis, who had been taking alendronate and alfacalcidol for approximately 6 years, suffered femur fractures following a fall in March 2012. Radiography revealed a subtrochanteric right femur fracture (Fig. [1](#Fig1){ref-type="fig"}a). In addition, her contralateral thigh showed thickening of the lateral cortex and a transverse radiolucent fracture line in the subtrochanter (Fig. [1](#Fig1){ref-type="fig"}b). The patient was diagnosed with AFFs. The patient had normal levels of bone resorption markers, but low levels of a bone formation marker (Table [1](#Tab1){ref-type="table"}).Fig. 1Radiograph imaging at the time of admission. **a** Radiograph imaging at the time of admission shows the right subtrochanteric fracture with breaking of the lateral cortex (*white arrow*) and spiking of the medial cortex (*black arrow*). **b** Zoomed image of the left thigh shows thickening of the lateral cortex (*white arrow*) and a transverse radiolucent fracture line (*black arrow*)Table 1Biochemical markers at the time of admissionParametersResultsReference rangeSerum calcium (mg/dL)8.98.7--10.3Serum phosphorous (mg/dL)2.72.5--4.7Serum alkaline phosphatase (U/L)163115--369Urine NTX (nmol BCE/mmol·Cre)17.114.3--89.0Serum TRACP-5b (mU/dL)257120--420Serum P1NP (μg/L)6.417.0--64.7^a^Serum ucOC (ng/mL)0.39\<4.50Serum homocysteine (nmol/mL)8.25.1--11.7Serum pentosidine (pg/mL)20.39.2--43.1*NTX* *N*-telopeptide of type I collagen, *P1NP* procollagen type 1*N*-terminal propeptide, *TRACP-5b* tartrate-resistant acid phosphatase type 5b, *ucOC* uncarboxylated osteocalcin^a^Postmenopausal

Four days after admission, the authors performed minimally invasive osteosynthesis using intramedullary nails (Fig. [2](#Fig2){ref-type="fig"}). Alfacalcidol was continued but alendronate was ceased. Two weeks later, low-intensity pulsed ultrasonography (LIPUS) therapy was started for both thigh regions to promote bone healing. In June 2012, radiography and computed tomography imaging revealed signs of delayed union at the right fracture site (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Radiograph imaging of the right thigh at the time of surgeryFig. 3Radiograph and CT imaging after 3 months of LIPUS therapy. **a** Radiograph imaging after 3 months of LIPUS therapy shows delayed union at the fracture site. **b** CT imaging after 3 months of LIPUS therapy shows delayed union at the fracture site. *CT* computerized tomography, *LIPUS* low-intensity pulsed ultrasonography

The patient could not walk without a crutch owing to contralateral thigh pain. After obtaining informed consent, prophylactic osteosynthesis was performed on the left subtrochanteric lesion in June 2012. Bone biopsy samples collected at the intramedullary nail insertion site revealed an absence of osteoblasts and osteoclasts on trabecular surfaces (Fig. [4](#Fig4){ref-type="fig"}), as well as low bone volume (Table [2](#Tab2){ref-type="table"}).Fig. 4Trabecular surfaces (×200 magnification, Villanueva bone stain) show a total absence of osteoblasts and osteoclasts (photomicrographs were taken at the Niigata Bone Science Institute, Niigata, Japan)Table 2Results of histomorphometric assessment of bone biopsy specimensParametersAbbreviationsResultsReference data^a^Bone volume Bone volumeBV/TV (%)11.5411.0 ± 1.8 Trabecular thicknessTb.Th (μm)103.09131.3 ± 28.1 Wall thicknessW.Th (μm)17.9628.3 ± 3.7Osteoid characteristics Osteoid volumeOV/TV (%)0.010.36 ± 0.31 Osteoid volumeOV/BV (%)0.061.6 ± 0.4 Osteoid surfaceOS/BS (%)1.0412.8 ± 2.2 Osteoid thicknessO.Th (μm)2.836.4 ± 0.8 Osteoblast surfaceOb.S/BS (%)NCResorption Eroded surfaceES/BS (%)0.063.0 ± 1.0 Osteoclast surfaceOc.S/BS (%)NC Fiber volumeFb.V/TV (%)0.000*NC* not calculated^a^Reference data from iliac crests of female over 71 years old

LIPUS treatment was restarted after surgery. In August 2012, once-weekly TPTD (56.5 μg) was added, and the patient's tartrate-resistant acid phosphatase type 5b (TRACP-5b) and procollagen type 1*N*-terminal propeptide (P1NP) levels increased transiently, as did their lumbar bone mineral density (Table [3](#Tab3){ref-type="table"}). After 3 months of TPTD treatment, the patient's fractures had improved (Fig. [5](#Fig5){ref-type="fig"}). Administration of TPTD was terminated in February 2013 and the patient can now walk independently without crutch.Table 3Treatment and changes in bone turnover markers and lumbar bone mineral densityParametersAdmission1 month3 months5 months6 months7 months10 months14 monthsTreatmentAlfacalcidolAlfacalcidol + LIPUSAlfacalcidol + LIPUSAlfacalcidol + LIPUS + TPTDAlfacalcidol + LIPUS + TPTDAlfacalcidol + LIPUS + TPTDAlfacalcidol + LIPUS + TPTDAlfacalcidolTRACP-5b (mU/dL)257380330460484400358261P1NP (μg/L)6.486.254.881.8906547.139Lumbar bone mineral density (g/cm^2^)0.845--0.826------0.8100.872*LIPUS* low-intensity pulsed ultrasonography, *P1NP* procollagen type 1*N*-terminal propeptide, *TPTD* teriparatide, *TRACP-5b* tartrate-resistant acid phosphatase type 5bFig. 5Radiograph and CT imaging after 3 months of TPTD therapy. **a** Radiograph imaging after 3 months of TPTD therapy shows complete union of fractures. **b** CT imaging after 3 months of TPTD therapy shows complete union of the right thigh fracture. **c** CT imaging after 3 months of TPTD therapy shows complete union of the left thigh fracture. *CT* computerized tomography, *TPTD* teriparatide

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from the patient for being included in the case report.

Discussion {#Sec3}
==========

The occurrence of AFFs associated with severely suppressed bone turnover (SSBT) in osteoporotic patients receiving bisphosphonates over prolonged periods was first reported in 2005 \[[@CR7]\]. A task force from the American Society for Bone and Mineral Research (ASBMR) defined the major and minor features of AFFs \[[@CR8]\], recommending that all major features should be present to confirm a diagnosis of AFF. Bisphosphonates effectively reduce the risk of femoral neck fractures in elderly women, but when continued for more than 5 years, the therapy can result in excessive suppression of bone turnover, thus increasing the risk of AFFs \[[@CR9]\].

The present case had an approximately 6-year history of alendronate therapy and subtrochanteric fractures with the major features designated by ASBMR; therefore, the case was diagnosed as having bisphosphonate-associated AFFs. Although urine *N*-telopeptide of type I collagen and serum TRACP-5b levels were normal, the patient's serum P1NP was low, suggesting reduced bone formation. Bone biopsy was performed at the intramedullary nail insertion site and undecalcified thin sections were made for trabecular bone histomorphometry. The data revealed a decrease in bone formation parameters (wall thickness, osteoid volume, osteoid surface, osteoid thickness, osteoblast surface) as well as a decrease in bone resorption parameters (eroded surface, osteoclast surface). It was speculated that the patient's bone turnover was extremely low in the proximal femur of this patient, and that SSBT attributed to alendronate use for more than 5 years led to their AFFs and delayed union. On the other hand, Zanchetta et al. \[[@CR10]\] reported that there were no distinctive microarchitecture features in the peripheral skeleton of a female patient who had suffered AFF while receiving bisphosphonate treatment. So, other factors including patient characteristics and instability of osteosynthesis might be concerned with AFFs and delayed union.

Union of both femur fractures was confirmed after 3 months of TPTD treatment. It was thought that TPTD stimulated the suppressed bone formation caused by long-term use of bisphosphonates. Two types of TPTD injection are available for treatment of osteoporosis in patients with a high risk of fracture in Japan: once-daily 20 μg or once-weekly 56.5 μg. It was thought that the increased bone formation owing to TPTD may have accelerated fracture healing and improved bone union. A search of the literature revealed several other similar clinical cases that were successfully treated with TPTD \[[@CR1]--[@CR6]\]. Aspenberg et al. \[[@CR11]\] showed a shorter healing time in postmenopausal women with dorsally angulated distal radial fractures who were treated once daily with TPTD 20 μg, compared with women treated with placebo. However, no difference in fracture healing time was observed between women treated once daily with TPTD 40 μg and women treated with placebo \[[@CR11]\]. Therefore, it appears that the dose of TPTD is important to achieve accelerated fracture repair. Although the patient in the current study received once-weekly TPTD, the overall dose received is considered closer to the once-daily 20 μg dose than to the once-daily 40 μg dose. Chiang et al. \[[@CR12]\] showed that once-daily TPTD 20 μg improved the bone quality and healing of AFFs associated with bisphosphonate therapy, while Mitani \[[@CR13]\] described a case in Japan showing nonunion of a femoral neck fracture who, like the patient in the current study, benefited from once-weekly treatment with TPTD 56.5 μg. Collectively, these findings \[[@CR13]\], together with the findings in the current case, suggest that fracture repair might be accelerated by once-weekly treatment with TPTD 56.5 μg, or once-daily treatment with TPTD 20 μg. Warden et al. \[[@CR14]\] reported in animal model that TPTD and LIPUS have contrasting additive effects during fracture healing, and the patient in the current case treated with TPTD and LIPUS, so the fracture repair might be due to the combination therapy. Based on the authors' experience, it is suggested that once-weekly TPTD treatment is beneficial for improving the healing of AFFs showing delayed union as well as other fracture treatment methods including electrical stimulation, bone graft, bone morphogenetic proteins, and LIPUS.

Conclusion {#Sec4}
==========

Suppressed bone formation caused by long-term bisphosphonate therapy can delay the union of fractures in osteoporotic patients. Although TPTD administration has been shown to accelerate the healing in such patients, it is not clear if daily or weekly treatments are required. The authors demonstrate in this report that weekly treatments are sufficient and should be considered for treating patients with AFFs with delayed union.
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